Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Weight Loss After Pregnancy AND Pregnancy

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44346   clinical trials with a EudraCT protocol, of which   7374   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    229 result(s) found for: Weight Loss After Pregnancy AND Pregnancy. Displaying page 3 of 12.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2009-016382-29 Sponsor Protocol Number: P1736-05/34/09 Start Date*: 2009-11-06
    Sponsor Name:Piramal Life Sciences Limited
    Full Title: A Phase II, 12-Week Randomised, Double-Blind, Placebo-Controlled, Proof of Concept Study to Evaluate Safety, Tolerability, Pharmacokinetics and Effect On Glycemic Control of P1736-05 in Subjects wi...
    Medical condition: Diabetes mellitus, type 2 (Blood Glucose Lowering Effect)/
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) HU (Completed) CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-005084-26 Sponsor Protocol Number: A5351019 Start Date*: 2007-01-18
    Sponsor Name:Pfizer Inc
    Full Title: A 2-YEAR, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY TO EVALUATE THE LONG-TERM EFFICACY AND SAFETY OF CP-945,598 IN THE TREATMENT OF OBESE SUBJECTS
    Medical condition: Obesity
    Disease: Version SOC Term Classification Code Term Level
    8.1 10029883 Obesity LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended) GB (Completed) FR (Completed) DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-000380-27 Sponsor Protocol Number: 192024-058Amendment3 Start Date*: 2011-06-21
    Sponsor Name:Allergan Ltd.
    Full Title: A Multicenter, Randomized, Double-blind, Parallel-group Study to Evaluate the Safety and Efficacy of Bimatoprost Solution 0.03%, 0.1%, and 0.3% Compared with Vehicle in Women with Female Pattern Ha...
    Medical condition: Female pattern hair loss
    Disease: Version SOC Term Classification Code Term Level
    14.0 10040785 - Skin and subcutaneous tissue disorders 10016407 Female pattern hair thinning LLT
    Population Age: Adults Gender: Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2020-004692-40 Sponsor Protocol Number: PPL20 Start Date*: 2021-03-30
    Sponsor Name:Dilafor AB
    Full Title: An Exploratory, Open label, Randomized, Parallel-Group, Pilot Study to evaluate Safety, Tolerability and Efficacy of daily, subcutaneous tafoxiparin treatment from the time of diagnosis for up to 4...
    Medical condition: Preeclampsia diagnosed at week 26-32 of gestation.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004868 10040444 Severe pre-eclampsia LLT
    Population Age: Adults Gender: Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2008-005075-10 Sponsor Protocol Number: CL08002 Start Date*: 2008-10-01
    Sponsor Name:BioCis Pharma Oy
    Full Title: Double-blind, vehicle-controlled, two-phase, single centre Phase I/IIa study with topical twice daily doses of 5% cis-urocanic acid to investigate pharmacokinetics, safety, tolerability and efficac...
    Medical condition: Chronic mild to moderate atopic dermatitis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-000501-23 Sponsor Protocol Number: B7451014 Start Date*: 2018-10-16
    Sponsor Name:Pfizer Inc., 235 East 42nd Street, New York, NY 10017
    Full Title: A phase 3 randomized withdrawal, double-blind, placebo-controlled, multi-center study investigating the efficacy and safety of PF-04965842 in subjects aged 12 years and over, with moderate to seve...
    Medical condition: Moderate to severe atopic dermatitis
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004858 10003639 Atopic dermatitis LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Completed) NL (Completed) BE (Completed) PL (Completed) DE (Completed) LV (Completed) SK (Completed) ES (Completed) IT (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2017-000626-35 Sponsor Protocol Number: D5670C00004 Start Date*: 2017-08-07
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase IIb, Randomised, Parallel, Double-Blind Placebo-Controlled and Open-Label Active Comparator Study to Evaluate the Efficacy and Safety of MEDI0382 in the Treatment of Overweight and Obese Su...
    Medical condition: Type 2 diabetes mellitus (T2DM)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) CZ (Completed) SK (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2010-023543-15 Sponsor Protocol Number: CL09002 Start Date*: 2011-01-24
    Sponsor Name:BioCis Pharma Oy
    Full Title: Double-blind, placebo-controlled, multi-centre Phase II study to investigate dose response, safety, tolerability and efficacy of topical twice daily doses of 2.5% and 5% cis-urocanic acid in compar...
    Medical condition: Chronic moderate or severe atopic dermatitis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-008332-90 Sponsor Protocol Number: CL08004 Start Date*: 2009-02-10
    Sponsor Name:BioCis Pharma Oy
    Full Title: Double-blind, vehicle-controlled, single centre Phase I/IIa study with topical twice daily doses of 5% cis-urocanic acid to investigate pharmacokinetics, safety, tolerability, and efficacy for up t...
    Medical condition: Mild to moderate plaque psoriasis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-002679-25 Sponsor Protocol Number: S60420 Start Date*: 2017-09-12
    Sponsor Name:KU Leuven
    Full Title: Characterization of colonic motility patterns in different functional bowel disorders compared to health and their role in moving content
    Medical condition: Functional bowel disorders; irritable bowel syndrome (constipation, diarrhea and mixed), chronic constipation, and chronic diarrhea.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2015-005499-46 Sponsor Protocol Number: Heparc-2008 Start Date*: 2016-06-24
    Sponsor Name:Arrowhead Pharmaceuticals, Inc.
    Full Title: A Multicenter, Open-Label Study to Evaluate ARC-520 Administered Alone and in Combination with Other Therapeutics in Patients with Chronic Hepatitis B Virus (HBV) Infection (MONARCH)
    Medical condition: Chronic Hepatitis B Virus (HBV) Infection
    Disease: Version SOC Term Classification Code Term Level
    19.0 10021881 - Infections and infestations 10008910 Chronic hepatitis B PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-003558-26 Sponsor Protocol Number: ABX464-103 Start Date*: 2019-12-10
    Sponsor Name:ABIVAX
    Full Title: A randomized, double blind, placebo controlled, parallel group, multiple dose, induction study to evaluate the safety, tolerability and optimal dose of ABX464 compared with placebo in patients with...
    Medical condition: Moderate to Severe Ulcerative Colitis
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004856 10066678 Acute ulcerative colitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) SI (Completed) CZ (Completed) DE (Completed) SK (Completed) HU (Completed) PL (Completed) BE (Completed) GB (GB - no longer in EU/EEA) IT (Completed)
    Trial results: View results
    EudraCT Number: 2006-002679-42 Sponsor Protocol Number: SNT-II-003 Start Date*: 2006-11-22
    Sponsor Name:Santhera Pharmaceuticals (Switzerland) Limited
    Full Title: A double blind, randomised, placebo-controlled study of the efficacy, safety and tolerability of idebenone in the treatment of patients with Leber's Hereditary Optic Neuropathy
    Medical condition: Leber's Hereditary Optic Neuropathy
    Disease:
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2020-000253-27 Sponsor Protocol Number: Pelle-926-301E Start Date*: 2020-06-05
    Sponsor Name:PellePharm, Inc.
    Full Title: A Phase 3, Multicenter, Open-Label Extension Study of Patidegib Topical Gel, 2% in Subjects with Gorlin Syndrome (Basal Cell Nevus Syndrome)
    Medical condition: Basal cell carcinomas (BCCs) in patients with Gorlin syndrome
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004850 10004151 Basal cell nevus syndrome LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) FR (Prematurely Ended) NL (Prematurely Ended) DK (Prematurely Ended) ES (Prematurely Ended) BE (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-004478-41 Sponsor Protocol Number: LCC001 Start Date*: 2015-03-10
    Sponsor Name:King's College London [...]
    1. King's College London
    2. Guy's and St Thomas' NHS Foundation Trust
    Full Title: Phase III trial in IntrahepaTic CHolestasis of pregnancy (ICP) to Evaluate urSodeoxycholic acid (UDCA) in improving perinatal outcomes
    Medical condition: Intrahepatic Cholestasis of pregnancy
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004871 10008638 Cholestasis intrahepatic LLT
    Population Age: Adults Gender: Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2020-002015-22 Sponsor Protocol Number: Strindfors2 Start Date*: 2022-08-12
    Sponsor Name:Dept. of Obstetrics and Gynecology, Sodersjukhuset
    Full Title: A pilot study and randomized placebo-controlled trial on the effect and timing of oral Tranexamic acid (TA) administered prepartum on postpartum haemorrhage after vaginal delivery
    Medical condition: Postpartum hemorrhage which is defined as bleeding during and after delivery that exceeds 500 ml. It is most commonly due to an atony of the uterus but may also have other causes such as tissue dam...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004868 10071867 Postpartum bleeding LLT
    Population Age: Adults Gender: Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-019638-28 Sponsor Protocol Number: PMR-EC-1211 Start Date*: 2010-11-22
    Sponsor Name:Astellas Pharma Europe Ltd.
    Full Title: INVESTIGATING NEW ONSET DIABETES MELLITUS IN KIDNEY TRANSPLANT RECIPIENTS RECEIVING AN ADVAGRAF-BASED IMMUNOSUPPRESSIVE REGIMEN WITH OR WITHOUT CORTICOSTEROIDS – A MULTICENTER, TWO ARM, RANDOMIZED...
    Medical condition: Prophylaxis of rejection in kidney allograft recipients (by immunosuppression)
    Disease: Version SOC Term Classification Code Term Level
    12.1 10050436 Prophylaxis against renal transplant rejection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) CZ (Completed) SK (Completed) HU (Completed) ES (Completed) LV (Completed) LT (Completed) EE (Completed) NL (Completed) SE (Completed) IT (Completed) DE (Completed) PT (Completed) BE (Completed) RO (Completed) FI (Completed)
    Trial results: View results
    EudraCT Number: 2018-000770-29 Sponsor Protocol Number: Ireland-RctV8 Start Date*: 2018-06-18
    Sponsor Name:The Rotunda Hospital
    Full Title: Investigating the role of early low-dose aspirin in diabetes: A phase III multicentre double-blinded placebo-controlled randomised trial of low-dose aspirin initiated in the first trimester of diab...
    Medical condition: Pregestational type I or type II diabetes
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004861 10045228 Type I diabetes mellitus LLT
    21.1 100000004861 10045242 Type II diabetes mellitus LLT
    Population Age: Adults Gender: Female
    Trial protocol: IE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-003575-38 Sponsor Protocol Number: 071101 Start Date*: 2015-01-07
    Sponsor Name:Baxalta Innovations GmbH
    Full Title: A PHASE 3 PROSPECTIVE, MULTICENTER STUDY TO EVALUATE EFFICACY AND SAFETY OF rVWF WITH OR WITHOUT ADVATE IN ELECTIVE SURGICAL PROCEDURES IN SUBJECTS WITH SEVERE VON WILLEBRAND DISEASE
    Medical condition: Hereditary severe von Willebrand Disease in adult patients who will undergo major and minor elective surgical procedures
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004850 10055168 Von Willebrand's factor deficiency LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Completed) IT (Completed) CZ (Completed) GB (Completed) NL (Completed) ES (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2017-003374-14 Sponsor Protocol Number: SAV008-01 Start Date*: 2018-04-06
    Sponsor Name:Savara ApS
    Full Title: An Open-label, non-controlled, multicenter, Pilot clinical Trial of Inhaled Molgramostim in subjects with Antibiotic-resistant non-tuberculosis mycobacterial (NTM) infection
    Medical condition: Treatment-resistant pulmonary non-tuberculosis mycobacterial (NTM) infection
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021881 - Infections and infestations 10062207 Mycobacterial infection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon Jun 30 08:33:17 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA